Germany Drug Cost-Benefit Proposal Departs From U.K., Other Approaches

Advisors to the German government have sketched an approach for evaluating drug costs relative to benefits that could depart significantly from the practices of established institutions like the U.K.'s National Institute for Health and Clinical Excellence